Long-term survival in venous thromboembolic disease: rivaroxaban vs. warfarin - propensity score matching study.

Autor: Ramos-Isaza E; Medicine at Facultad de Medicina, Universidad de La Sabana, Universidad de La Sabana, Km 7, Autonorte de Bogota, Chía, Cundinamarca, 250001, Colombia., Tuta-Quintero E; Medicine at Facultad de Medicina, Universidad de La Sabana, Universidad de La Sabana, Km 7, Autonorte de Bogota, Chía, Cundinamarca, 250001, Colombia., Bastidas-Goyes A; Medicine at Facultad de Medicina, Universidad de La Sabana, Universidad de La Sabana, Km 7, Autonorte de Bogota, Chía, Cundinamarca, 250001, Colombia. alirio.bastidas@unisabana.edu.co., Diaz-Quijano D; Medicine at Facultad de Medicina, Universidad de La Sabana, Universidad de La Sabana, Km 7, Autonorte de Bogota, Chía, Cundinamarca, 250001, Colombia., Aponte-Murcia C; Clinica Universidad de La Sabana, Chía, Colombia., Espitia-Angel J; Medicine at Facultad de Medicina, Universidad de La Sabana, Universidad de La Sabana, Km 7, Autonorte de Bogota, Chía, Cundinamarca, 250001, Colombia., Pinto-Beltran D; Medicine at Facultad de Medicina, Universidad de La Sabana, Universidad de La Sabana, Km 7, Autonorte de Bogota, Chía, Cundinamarca, 250001, Colombia., Rincón-Hernández J; Medicine at Facultad de Medicina, Universidad de La Sabana, Universidad de La Sabana, Km 7, Autonorte de Bogota, Chía, Cundinamarca, 250001, Colombia., Sánchez-Cuellar J; Medicine at Facultad de Medicina, Universidad de La Sabana, Universidad de La Sabana, Km 7, Autonorte de Bogota, Chía, Cundinamarca, 250001, Colombia., Pérez-Bueno J; Medicine at Facultad de Medicina, Universidad de La Sabana, Universidad de La Sabana, Km 7, Autonorte de Bogota, Chía, Cundinamarca, 250001, Colombia., Giraldo-Cadavid LF; Medicine at Facultad de Medicina, Universidad de La Sabana, Universidad de La Sabana, Km 7, Autonorte de Bogota, Chía, Cundinamarca, 250001, Colombia.; Chief of the Interventional Pulmonology Service, Facultad de Medicina, Fundacion Neumologica Colombiana, Universidad de La Sabana, Bogotá, Colombia.
Jazyk: angličtina
Zdroj: BMC pharmacology & toxicology [BMC Pharmacol Toxicol] 2023 Dec 13; Vol. 24 (1), pp. 77. Date of Electronic Publication: 2023 Dec 13.
DOI: 10.1186/s40360-023-00712-8
Abstrakt: Background: Venous thromboembolic disease (VTE) is characterized by obstruction of venous blood flow by a thrombus. Survival data, frequency of disease recurrence, and bleeding rate in patients on anticoagulant therapy with warfarin compared to rivaroxaban in the Latin American population are limited in VTE.
Methods: A retrospective cohort study with propensity score matching analysis was conducted in patients with pulmonary embolism and/or deep vein thrombosis anticoagulated with warfarin or rivaroxaban treated. Survival analysis was performed using a Kaplan-Meier curve for each of the intervention groups, and it was compared using a Log Rank test.
Results: Of 2193 potentially eligible patients with a suspected diagnosis of VTE, 505 patients entered the analysis; of these, 285 subjects were managed with warfarin and 220 anticoagulated with rivaroxaban. Major bleeding at 12 months occurred in 2.7% (6/220) of patients treated with Rivaroxaban, compared to 10.2% (29/285) in the Warfarin group in the unmatched population (p = 0.001). In the matched population, bleeding at 12 months occurred in 2.9% (6/209) of patients on Rivaroxaban and in 11.0% (23/209) of patients on Warfarin (p = 0.001). The survival rates at 6 months were 97.1% for Rivaroxaban and 97.6% for Warfarin (p = 0.76). At 12 months, the survival rates were 94.7% for Rivaroxaban and 95.7% for Warfarin (p = 0.61).
Conclusion: In the treatment of VTE, there is no differences on 6 and 12-month survival or a reduction in the occurrence of new thromboembolic events when comparing rivaroxaban to warfarin. However, a lower risk of major bleeding is observed at 12 months with Rivaroxaban.
(© 2023. The Author(s).)
Databáze: MEDLINE
Externí odkaz: